BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 09, 2015
 |  BioCentury  |  Emerging Company Profile

Neo frontier

Why Gritstone thinks neoantigens are immuno-oncology's new frontier

Gritstone Oncology Inc. is developing personalized neoantigen-based vaccines that it expects to deliver to non-small cell lung cancer patients within a month of sequencing their tumors. To go from sequence to vaccine, the company will have to build its platform from scratch, answer a host of biological questions and select a method for delivering the antigens.

President and CEO Andrew Allen is charting an aggressive course to the clinic, thanks to a huge series A round that will enable the company to conduct multiple experiments in parallel. In October, Gritstone raised $102 million in a series A round, which Allen said should get the company through 2017.

"With our capital we can run all these experiments in parallel and get to the goal line as soon as possible," Allen told BioCentury. "I want to be in the clinic in a year."

Most of the company's platform will consist of technologies that are commercially available, such as sequencing technology, or that will be licensed, such as vaccine delivery modalities.

Gritstone's proprietary contribution will be selecting the neoantigens to...

Read the full 895 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >